Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556].
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P.
Blasi M, et al. Among authors: thomas m.
Eur J Cancer. 2024 May 24:114130. doi: 10.1016/j.ejca.2024.114130. Online ahead of print.
Eur J Cancer. 2024.
PMID: 38789333
No abstract available.